Form 4 for TMO Thermo Fisher Scientific
Accepted 2024-02-23 00:00:00 ET · period of report 2024-02-21 · accession 0001127602-24-006591 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-23 | 2024-02-21 | TMO | Pettiti Gianluca | EVP | A - Grant | $0.00 | +2,093 | 19.6K | +12% | $0 |
| DM | 2024-02-23 | 2024-02-21 | TMO | Pettiti Gianluca | EVP | A - Grant | $0.00 | +27.3K | 13.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-21 | A | A | 2,093 | $0.00 | 19,648.67 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-02-21 | A | A | 14,300 | $0.00 | 14,300 | D | $418.32 · 2024-03-09 to 2027-09-09 | 14,300 Common Stock | (F2) This performance-based stock option award was granted on September 9, 2020. The Company's Compensation Committee certified on February 21, 2024 that the performance criteria related to this award were satisfied. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-02-21 | A | A | 13,047 | $0.00 | 13,047 | D | $552.85 · — to 2032-02-21 | 13,047 Common Stock | (F1) The option vests in four equal annual installments beginning on February 28, 2025. |